Neurocrine Gets First Drug For Tardive Dyskinesia To FDA
Executive Summary
Neurocrine submits NDA for its VMAT inhibitor valbenazine for tardive dyskinesia, getting to FDA ahead of Teva, which is developing a similar product, deutetrabenazine, for the same indication.